CVS Health Corp
XMUN:CVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
CVS Health Corp
XMUN:CVS
|
US |
|
T
|
Thai Coconut PCL
SET:COCOCO
|
TH |
|
Komercni Banka as
PSE:KOMB
|
CZ |
|
C
|
Calgro M3 Holdings Ltd
OTC:CLMHF
|
ZA |
|
M
|
Monster Beverage Corp
SWB:MOB
|
US |
|
D
|
Dillard's Inc
F:DL7A
|
US |
|
T
|
Truist Financial Corp
XMUN:BBK
|
US |
|
C
|
Chai Watana Tannery Group PCL
SET:CWT
|
TH |
|
G
|
G J Steel PCL
SET:GJS
|
TH |
|
Nestle SA
SIX:NESN
|
CH |
|
M
|
Meta Epsi Tbk PT
IDX:MTPS
|
ID |
|
S
|
Sjf Bank A/S
F:4AC
|
DK |
|
European Medical Solutions SA
F:AS00
|
FR |
|
Calix Ltd
OTC:CLXLF
|
AU |
|
Cimpress PLC
NASDAQ:CMPR
|
IE |
|
G
|
Glory Forever PCL
SET:GLORY
|
TH |
|
A
|
AIB Group PLC
DUS:A5G
|
IE |
|
G
|
GEE Group Inc
F:4LU
|
US |
|
S
|
Sherwood Corporation (Thailand) PCL
SET:SWC
|
TH |
|
P
|
PGF Capital Bhd
KLSE:PGF
|
MY |
|
Tenaga Nasional Bhd
OTC:TNABF
|
MY |
|
Barings BDC Inc
NYSE:BBDC
|
US |
|
P
|
Pilulka Lekarny as
PSE:PINK
|
CZ |
|
A
|
Aristocrat Leisure Ltd
XMUN:AC8
|
AU |
Earnings Calls
Last Earnings Call
Beat and raise: CVS said each operating segment beat expectations in Q2, with adjusted operating income of $5.2 billion and adjusted EPS of $2.58, and it raised full-year 2026 EPS guidance by $0.60 to $7.90 to $8.10.
Guidance lifted: The company also raised full-year cash flow from operations to at least $11.5 billion, up $2 billion from prior guidance, and now expects revenue of at least $414 billion.
Aetna improved: Health Care Benefits delivered stronger-than-expected results, with Medicare ahead of plan and overall margin recovery continuing as medical cost management and pricing discipline showed through.
PBM pressure flagged: Management said 340B pressure will remain a headwind into 2027, and it also expects Caremark membership declines next year as it renews business more cautiously.
Retail momentum: CVS Pharmacy and PCW continued to show strong momentum, helped by prescription growth, Rite Aid-related volume, and improving service levels, while management said its cost-based pricing model is helping stabilize margins.
AI and GLP-1s: Management leaned heavily on technology and AI as both a cost saver and growth driver, and highlighted GLP-1 access as a consumer opportunity across funded, cash-pay, pharmacy, and clinic channels.